Dr. Gentzler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-243-6086
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2008 - 2011
- Lewis Katz School of Medicine at Temple UniversityClass of 2008
- Davidson CollegeBS, 2000 - 2004
Certifications & Licensure
- VA State Medical License 2014 - 2026
- IL State Medical License 2011 - 2014
- PA State Medical License 2008 - 2011
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
- Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Start of enrollment: 2015 Mar 09
- Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Start of enrollment: 2015 Jun 04
- Join now to see all
Publications & Presentations
PubMed
- 1053 citationsCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-...Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik
The Lancet. Oncology. 2016-11-01 - 163 citations24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small ...Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, Amita Patnaik
Journal of Thoracic Oncology. 2019-01-01 - 87 citationsLong-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang
Journal of Thoracic Oncology. 2021-01-01
Press Mentions
- UVA Cancer Center 1st in State to Offer New Lung Cancer TreatmentAugust 19th, 2024
- UVA Cancer Center Pioneers New Lung Cancer Treatment in VirginiaAugust 19th, 2024
- UVA Cancer Center First in Virginia to Offer New Lung Cancer TreatmentAugust 19th, 2024
- Join now to see all
Professional Memberships
- Member
- International Association for the Study of Lung Cancer (IASLC)Member
- European Society of Medical OncologyMember
External Links
- UVA Physician Profilehttp://cancer.uvahealth.com/findadoctor/profile/Ryan-Gentzler
- UVA Cancer Centerhttp://cancer.uvahealth.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: